AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial

By /

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its cardiovascular and kidney disease pipelines.

Scroll to Top